Identifier
Created
Classification
Origin
06TOKYO6098
2006-10-19 08:00:00
UNCLASSIFIED
Embassy Tokyo
Cable title:
AVIAN INFLUENZA: JAPAN WEEKLY REPORT OCTOBER 19
how-toVZCZCXRO3770 PP RUEHHM RUEHLN RUEHMA RUEHPB DE RUEHKO #6098 2920800 ZNR UUUUU ZZH P 190800Z OCT 06 FM AMEMBASSY TOKYO TO RUEHC/SECSTATE WASHDC PRIORITY 7597 INFO RUEHZN/ENVIRONMENT SCIENCE AND TECHNOLOGY COLLECTIVE RUEHFK/AMCONSUL FUKUOKA 8516 RUEHNAG/AMCONSUL NAGOYA 8199 RUEHNH/AMCONSUL NAHA 1052 RUEHOK/AMCONSUL OSAKA KOBE 1895 RUEHKSO/AMCONSUL SAPPORO 9585 RUEHRC/USDA FAS WASHDC 8354 RUEAUSA/DEPT OF HHS WASHINGTON DC RUEAIIA/CIA WASHDC
UNCLAS TOKYO 006098
SIPDIS
DEPT FOR AIAG AMBASSADOR LANGE
DEPT FOR OES/IHA SINGER AND FENDRICK
DEPT FOR EAP/J
USDA PASS TO APHIS
HHS PASS TO CDC
HHS FOR OGHA STEIGER, BHAT AND ELVANDER
DEPT PASS TO AID/GH/HIDN DENNIS CARROLL
SIPDIS
E.O. 12958: N/A
TAGS: TBIO KFLU KSTH ECON PREL SOCI JA
SUBJECT: AVIAN INFLUENZA: JAPAN WEEKLY REPORT OCTOBER 19
REF: A. 05 STATE 153802
B. TOKYO 5970 AND PREVIOUS
UNCLAS TOKYO 006098
SIPDIS
DEPT FOR AIAG AMBASSADOR LANGE
DEPT FOR OES/IHA SINGER AND FENDRICK
DEPT FOR EAP/J
USDA PASS TO APHIS
HHS PASS TO CDC
HHS FOR OGHA STEIGER, BHAT AND ELVANDER
DEPT PASS TO AID/GH/HIDN DENNIS CARROLL
SIPDIS
E.O. 12958: N/A
TAGS: TBIO KFLU KSTH ECON PREL SOCI JA
SUBJECT: AVIAN INFLUENZA: JAPAN WEEKLY REPORT OCTOBER 19
REF: A. 05 STATE 153802
B. TOKYO 5970 AND PREVIOUS
1. There were no significant avian influenza (AI)
developments in Japan during the period October 13 to
October 19. No human or animal outbreaks of H5N1 AI were
reported in Japan during the above period.
-- Japanese Developers Confirm the Effectiveness of a New
AI Vaccine for Humans --
1. On October 17, four Japanese vaccine developers,
including the Kitasato Research Institute, announced that
they have confirmed the effectiveness of a new vaccine for
human-to-human transmitted pandemic influenza. The vaccine
was developed using an H5N1 AI virus taken from a human
case of H5N1 infection in Vietnam, and has been in
development, in cooperation with the National Institute of
Infectious Diseases, since 2004. In July of this year, a
phase I clinical trial of 360 healthy adult males confirmed
both the vaccine's effectiveness in increasing levels of
antibodies and its safety to humans. Large-scale phase II
and III clinical trials began in September. The vaccine's
developers plan to request approval from the Ministry of
Health, Labor and Welfare to produce and sell the vaccine
in 2007.
SCHIEFFER
SIPDIS
DEPT FOR AIAG AMBASSADOR LANGE
DEPT FOR OES/IHA SINGER AND FENDRICK
DEPT FOR EAP/J
USDA PASS TO APHIS
HHS PASS TO CDC
HHS FOR OGHA STEIGER, BHAT AND ELVANDER
DEPT PASS TO AID/GH/HIDN DENNIS CARROLL
SIPDIS
E.O. 12958: N/A
TAGS: TBIO KFLU KSTH ECON PREL SOCI JA
SUBJECT: AVIAN INFLUENZA: JAPAN WEEKLY REPORT OCTOBER 19
REF: A. 05 STATE 153802
B. TOKYO 5970 AND PREVIOUS
1. There were no significant avian influenza (AI)
developments in Japan during the period October 13 to
October 19. No human or animal outbreaks of H5N1 AI were
reported in Japan during the above period.
-- Japanese Developers Confirm the Effectiveness of a New
AI Vaccine for Humans --
1. On October 17, four Japanese vaccine developers,
including the Kitasato Research Institute, announced that
they have confirmed the effectiveness of a new vaccine for
human-to-human transmitted pandemic influenza. The vaccine
was developed using an H5N1 AI virus taken from a human
case of H5N1 infection in Vietnam, and has been in
development, in cooperation with the National Institute of
Infectious Diseases, since 2004. In July of this year, a
phase I clinical trial of 360 healthy adult males confirmed
both the vaccine's effectiveness in increasing levels of
antibodies and its safety to humans. Large-scale phase II
and III clinical trials began in September. The vaccine's
developers plan to request approval from the Ministry of
Health, Labor and Welfare to produce and sell the vaccine
in 2007.
SCHIEFFER